See more : Subsea 7 S.A. (SUBCY) Income Statement Analysis – Financial Results
Complete financial analysis of Imunon, Inc. (0HUZ.L) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Imunon, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- PT Cashlez Worldwide Indonesia Tbk (CASH.JK) Income Statement Analysis – Financial Results
- Vitality Prime, Inc. (VPIM) Income Statement Analysis – Financial Results
- Avolta AG (DFRYF) Income Statement Analysis – Financial Results
- Silver Spike Investment Corp. (SSIC) Income Statement Analysis – Financial Results
- Tingo Group, Inc. (TIOG) Income Statement Analysis – Financial Results
Imunon, Inc. (0HUZ.L)
About Imunon, Inc.
Imunon, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. The company was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. Imunon, Inc. was founded in 1982 and is based in Lawrenceville, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 500.00K | 500.00K | 500.00K | 500.00K | 500.00K | 500.00K | 500.00K | 500.00K | 500.00K | 500.00K | 0.00 |
| Cost of Revenue | 720.01K | 731.63K | 702.92K | 11.34M | 13.07M | 11.07M | 13.08M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -720.01K | -231.63K | -202.92K | -10.84M | -12.57M | -10.57M | -12.58M | 500.00K | 500.00K | 500.00K | 500.00K | 0.00 |
| Gross Profit Ratio | 0.00% | -46.33% | -40.58% | -2,168.96% | -2,513.06% | -2,113.10% | -2,515.74% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% |
| Research & Development | 11.29M | 11.73M | 10.62M | 11.34M | 13.07M | 11.87M | 13.08M | 14.62M | 14.66M | 14.97M | 9.36M | 15.77M |
| General & Administrative | 9.74M | 13.69M | 10.89M | 7.64M | 8.00M | 9.70M | 5.89M | 6.53M | 6.69M | 8.86M | 6.55M | 6.37M |
| Selling & Marketing | 0.00 | -731.63K | -702.92K | -741.52K | -721.67K | -356.86K | -553.01K | -1.03M | -432.47K | 0.00 | 0.00 | 0.00 |
| SG&A | 9.74M | 12.96M | 10.18M | 6.90M | 7.28M | 9.34M | 5.34M | 5.50M | 6.25M | 8.86M | 6.55M | 6.37M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 21.03M | 24.69M | 20.80M | 18.24M | 20.34M | 21.21M | 18.42M | 20.12M | 20.91M | 24.75M | 7.84M | 26.26M |
| Cost & Expenses | 21.03M | 25.42M | 21.51M | 18.99M | 21.07M | 21.57M | 18.97M | 21.15M | 21.35M | 24.75M | 7.84M | 26.26M |
| Interest Income | 725.82K | 502.58K | 18.15K | 66.55K | 442.99K | 358.34K | 65.72K | 696.07K | 1.29M | 1.25M | 915.24K | 307.09K |
| Interest Expense | 197.08K | 5.03M | 569.88K | 1.29M | 1.39M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 248.15K | 731.63K | 702.92K | 741.52K | 721.67K | 356.86K | 553.01K | 1.03M | 432.47K | 376.83K | 346.73K | 288.99K |
| EBITDA | -20.78M | -24.19M | -20.30M | -17.74M | -19.84M | -21.23M | -17.92M | -19.62M | -20.41M | -23.79M | -15.06M | -21.85M |
| EBITDA Ratio | 0.00% | -4,837.99% | -4,060.85% | -3,548.98% | -3,968.76% | -4,141.64% | -3,583.08% | -3,924.27% | -4,082.86% | -4,590.62% | -3,012.95% | 0.00% |
| Operating Income | -21.03M | -24.92M | -21.01M | -18.49M | -20.57M | -21.07M | -18.47M | -20.65M | -20.85M | -23.33M | -15.41M | -22.14M |
| Operating Income Ratio | 0.00% | -4,984.31% | -4,201.44% | -3,697.28% | -4,113.09% | -4,213.01% | -3,693.69% | -4,129.96% | -4,169.36% | -4,665.99% | -3,082.30% | 0.00% |
| Total Other Income/Expenses | 235.07K | -12.54M | -1.15M | -4.84M | 1.90M | -1.24M | -1.93M | -1.40M | -1.61M | -2.16M | 7.16M | -4.43M |
| Income Before Tax | -20.80M | -37.47M | -22.15M | -23.33M | -18.67M | -22.30M | -20.40M | -22.05M | -22.46M | -25.49M | -8.25M | -26.57M |
| Income Before Tax Ratio | 0.00% | -7,493.05% | -4,430.54% | -4,665.88% | -3,733.60% | -4,460.49% | -4,080.44% | -4,410.75% | -4,492.22% | -5,098.85% | -1,650.27% | 0.00% |
| Income Tax Expense | -1.28M | -1.57M | -1.38M | -1.85M | -1.82M | -10.42M | 345.69K | -4.00 | 4.00 | 0.00 | 4.60M | 0.00 |
| Net Income | -19.51M | -35.90M | -20.77M | -21.48M | -16.85M | -11.88M | -20.75M | -22.05M | -22.46M | -25.49M | -12.85M | -26.57M |
| Net Income Ratio | 0.00% | -7,179.65% | -4,153.85% | -4,296.71% | -3,370.31% | -2,376.67% | -4,149.57% | -4,410.75% | -4,492.22% | -5,098.85% | -2,570.55% | 0.00% |
| EPS | -2.16 | -5.03 | -57.41 | -10.08 | -11.58 | -10.14 | -40.80 | -178.42 | -216.24 | -289.83 | -199.33 | -721.69 |
| EPS Diluted | -2.16 | -5.03 | -57.41 | -10.08 | -11.58 | -10.14 | -40.80 | -178.42 | -216.24 | -289.83 | -199.34 | -721.69 |
| Weighted Avg Shares Out | 9.05M | 7.14M | 361.80K | 2.13M | 1.46M | 1.17M | 508.48K | 123.60K | 103.87K | 87.96K | 64.48K | 36.81K |
| Weighted Avg Shares Out (Dil) | 9.05M | 7.14M | 361.80K | 2.13M | 1.46M | 1.17M | 508.48K | 123.60K | 103.87K | 87.96K | 64.48K | 36.81K |
Source: https://incomestatements.info
Category: Stock Reports